Marwa Amer, D. Mahgoub, D. Kadry, Ghada Ahmed, Laila A. Rashed, Basma Gaballah, Marwa Kamel
Background In psoriasis, interleukin (IL)-36 is considered a pathogenic driver, whereas IL-38 was downregulated. Little is known about their role in metabolic syndrome (Ms) in psoriasis. Objective To evaluate a possible relation between serum IL-36 and IL-38 and Ms in psoriasis vulgaris. Patients and methods This study was designed as a case–control study. It included 80 participants, who were divided into four groups: group A included 20 psoriasis patients with Ms, group B included 20 psoriasis patients without Ms, group C included 20 controls with Ms, and group D included 20 healthy controls. Written informed consents were signed by all participants. Clinical examination and psoriasis area and severity index (PASI) evaluation were done. BMI, waist circumference, arterial blood pressure, fasting blood glucose, and lipid profile were measured. Blood samples were withdrawn, and serum IL-36 and IL-38 levels were measured using enzyme-linked immunosorbent assay. Results Serum IL-36 levels were significantly higher in group A (mean±SD=187.84±32.84 pg/ml) compared with group B (mean±SD=156.5±24.09 pg/ml) (P<0.001), or group C (mean±SD=115.18±14.69 pg/ml) (P<0.001) or group D (mean±SD=38.06±10.18 pg/ml) (P<0.001). Serum IL-38 levels were significantly lower in group A (mean±SD 57.34±19.91 pg/ml) compared with group B (mean±SD=73.9±16.13 pg/ml) (P<0.006) or group C (mean±SD=74.67±12.89 pg/ml) (P=0.002), or group D (mean±SD=212.36±17.55 pg/ml) (P<0.001). In group A, IL-36 had a 75% sensitivity and 70% specificity with a cutoff value of 166.2, whereas IL-38 had an 80% sensitivity and 65% specificity with a cutoff value of 74. There was a significant negative correlation between IL36 and IL-38 levels (r=−0.637, P<0.001). Conclusion Patients with psoriasis with Ms had significantly higher IL-36 and lower IL-38. Imbalance between IL-36 and IL-38 may be associated with underlying metabolic disturbance seen in psoriasis.
{"title":"Imbalance between serum interleukin-36 and interleukin-38 is associated with metabolic syndrome in psoriasis vulgaris","authors":"Marwa Amer, D. Mahgoub, D. Kadry, Ghada Ahmed, Laila A. Rashed, Basma Gaballah, Marwa Kamel","doi":"10.4103/jewd.jewd_14_23","DOIUrl":"https://doi.org/10.4103/jewd.jewd_14_23","url":null,"abstract":"Background In psoriasis, interleukin (IL)-36 is considered a pathogenic driver, whereas IL-38 was downregulated. Little is known about their role in metabolic syndrome (Ms) in psoriasis. Objective To evaluate a possible relation between serum IL-36 and IL-38 and Ms in psoriasis vulgaris. Patients and methods This study was designed as a case–control study. It included 80 participants, who were divided into four groups: group A included 20 psoriasis patients with Ms, group B included 20 psoriasis patients without Ms, group C included 20 controls with Ms, and group D included 20 healthy controls. Written informed consents were signed by all participants. Clinical examination and psoriasis area and severity index (PASI) evaluation were done. BMI, waist circumference, arterial blood pressure, fasting blood glucose, and lipid profile were measured. Blood samples were withdrawn, and serum IL-36 and IL-38 levels were measured using enzyme-linked immunosorbent assay. Results Serum IL-36 levels were significantly higher in group A (mean±SD=187.84±32.84 pg/ml) compared with group B (mean±SD=156.5±24.09 pg/ml) (P<0.001), or group C (mean±SD=115.18±14.69 pg/ml) (P<0.001) or group D (mean±SD=38.06±10.18 pg/ml) (P<0.001). Serum IL-38 levels were significantly lower in group A (mean±SD 57.34±19.91 pg/ml) compared with group B (mean±SD=73.9±16.13 pg/ml) (P<0.006) or group C (mean±SD=74.67±12.89 pg/ml) (P=0.002), or group D (mean±SD=212.36±17.55 pg/ml) (P<0.001). In group A, IL-36 had a 75% sensitivity and 70% specificity with a cutoff value of 166.2, whereas IL-38 had an 80% sensitivity and 65% specificity with a cutoff value of 74. There was a significant negative correlation between IL36 and IL-38 levels (r=−0.637, P<0.001). Conclusion Patients with psoriasis with Ms had significantly higher IL-36 and lower IL-38. Imbalance between IL-36 and IL-38 may be associated with underlying metabolic disturbance seen in psoriasis.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"154 - 161"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70792344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmed Hamed, Amal Abdelmaksoud, Asmaa Elfallah, Enas Sweed, Samah Ibrahim
Background Alopecia areata (AA) is a prevalent autoimmune skin disease that may be associated with systemic disorders. The connection between cardiovascular risks and AA is not widely investigated. Chemokine (C-C motif) ligand 20 (CCL20) has been found to be related to cardiovascular comorbidities. Objective To investigate the role of CCL20 in AA patients and its relation to cardiovascular comorbidity. Patients and methods This study enrolled 80 AA patients and 40 age and sex-matched control subjects. Serums CCL20, high sensitive C- reactive protein (Hs-CRP), lipid profile in addition to carotid intima-media thickness (CIMT) were investigated in all subjects. Results AA patients expressed significantly higher serum CCL20 levels than healthy controls (29.6±20.4 vs. 10.3±6.7, P <0.001). Serum CCL20 was significantly correlated with total cholesterol (TC), low-density lipoprotein (LDL), triglycerides (TGs), and CIMT (p value: 0.002, 0.044, <0.001, <0.001, respectively). Regression analysis was conducted for prediction of CV increased risk and revealed that older age, higher LDL, TC, TG, HS-CRP, CCL2, lower HDL and presence of alopecia were associated with risk of higher CIMT in univariable analysis. Conclusion Serum CCL20 might have a role in AA pathogenesis. It may serve a new possible link between AA and both systemic inflammation and cardiovascular risk observed in AA patients.
{"title":"Serum CCL20: A novel potential marker of cardiovascular risk in alopecia areata patients","authors":"Ahmed Hamed, Amal Abdelmaksoud, Asmaa Elfallah, Enas Sweed, Samah Ibrahim","doi":"10.4103/jewd.jewd_27_23","DOIUrl":"https://doi.org/10.4103/jewd.jewd_27_23","url":null,"abstract":"Background Alopecia areata (AA) is a prevalent autoimmune skin disease that may be associated with systemic disorders. The connection between cardiovascular risks and AA is not widely investigated. Chemokine (C-C motif) ligand 20 (CCL20) has been found to be related to cardiovascular comorbidities. Objective To investigate the role of CCL20 in AA patients and its relation to cardiovascular comorbidity. Patients and methods This study enrolled 80 AA patients and 40 age and sex-matched control subjects. Serums CCL20, high sensitive C- reactive protein (Hs-CRP), lipid profile in addition to carotid intima-media thickness (CIMT) were investigated in all subjects. Results AA patients expressed significantly higher serum CCL20 levels than healthy controls (29.6±20.4 vs. 10.3±6.7, P <0.001). Serum CCL20 was significantly correlated with total cholesterol (TC), low-density lipoprotein (LDL), triglycerides (TGs), and CIMT (p value: 0.002, 0.044, <0.001, <0.001, respectively). Regression analysis was conducted for prediction of CV increased risk and revealed that older age, higher LDL, TC, TG, HS-CRP, CCL2, lower HDL and presence of alopecia were associated with risk of higher CIMT in univariable analysis. Conclusion Serum CCL20 might have a role in AA pathogenesis. It may serve a new possible link between AA and both systemic inflammation and cardiovascular risk observed in AA patients.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"19 1","pages":"173 - 178"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70792698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Platelet-rich plasma (PRP) is a promising treatment method of alopecia, but there is a debate about its role in the treatment of alopecia areata. Intralesional steroid is the first-line treatment option for patchy alopecia areata. Combination therapy represents an option for increasing the efficacy of the different lines of treatment. Objective To compare the therapeutic efficacy of traditional treatment of alopecia areata with intralesional injection of triamcinolone acetonide versus combination therapy with intralesional triamcinolone acetonide and intralesional PRP alternatively. Patients and methods In this comparative randomized single-blinded study, 30 patients with two nonadjacent patches of alopecia areata were included. One patch was treated with intralesional triamcinolone acetonide alone (group I) every 4 weeks for 3 months, and the other patch was treated with intralesional triamcinolone acetonide alternating with intralesional PRP (group II) every 2 weeks for 3 months. Evaluation was done by MacDonald Hull and Norris grading and dermoscopy. Results A significant increase in the mean grading score was noted before each intralesional steroid injection session in both groups. However, group II patches treated with intralesional triamcinolone acetonide alternating with intralesional PRP showed significantly higher mean grading score as compared with group I patches treated with intralesional triamcinolone acetonide alone. The dermoscopic features of alopecia areata significantly decrease or disappear at the end of treatment sessions in both groups. Conclusion Combined use of intralesional steroid and intralesional PRP in the treatment of alopecia areata yields better results than using intralesional steroid alone and could be considered as a more effective line of treatment. However, further research studies are needed to determine the optimal dose, intervals, and duration of treatment.
{"title":"Combined intralesional platelet-rich plasma and intralesional steroid versus intralesional steroid alone in the treatment of alopecia areata","authors":"Ashraf M. Hamza, Asmaa Elsayed, Ahmed Abdel-Bary","doi":"10.4103/jewd.jewd_53_22","DOIUrl":"https://doi.org/10.4103/jewd.jewd_53_22","url":null,"abstract":"Background Platelet-rich plasma (PRP) is a promising treatment method of alopecia, but there is a debate about its role in the treatment of alopecia areata. Intralesional steroid is the first-line treatment option for patchy alopecia areata. Combination therapy represents an option for increasing the efficacy of the different lines of treatment. Objective To compare the therapeutic efficacy of traditional treatment of alopecia areata with intralesional injection of triamcinolone acetonide versus combination therapy with intralesional triamcinolone acetonide and intralesional PRP alternatively. Patients and methods In this comparative randomized single-blinded study, 30 patients with two nonadjacent patches of alopecia areata were included. One patch was treated with intralesional triamcinolone acetonide alone (group I) every 4 weeks for 3 months, and the other patch was treated with intralesional triamcinolone acetonide alternating with intralesional PRP (group II) every 2 weeks for 3 months. Evaluation was done by MacDonald Hull and Norris grading and dermoscopy. Results A significant increase in the mean grading score was noted before each intralesional steroid injection session in both groups. However, group II patches treated with intralesional triamcinolone acetonide alternating with intralesional PRP showed significantly higher mean grading score as compared with group I patches treated with intralesional triamcinolone acetonide alone. The dermoscopic features of alopecia areata significantly decrease or disappear at the end of treatment sessions in both groups. Conclusion Combined use of intralesional steroid and intralesional PRP in the treatment of alopecia areata yields better results than using intralesional steroid alone and could be considered as a more effective line of treatment. However, further research studies are needed to determine the optimal dose, intervals, and duration of treatment.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"98 - 105"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46167970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eman H Elmorsy, Eman Alsawy, Basma Elsronbawy, Alsayeda A A Taha
Background Psoriasis is a noninfectious, inflammatory, and hyperproliferative skin disorder. Cyclin-dependent kinase 2 (CDK2) is a serine-threonine protein kinase that plays a role in the transition of G1/S, the initiation of DNA synthesis, and the regulation of the S phase exit in the cell cycle. CDK2 is uniformly expressed in healthy human epidermis being located mainly in the cytoplasm and nuclei of basal keratinocytes. Objective To compare the CDK2 density by immunohistochemistry in lesional versus nonlesional psoriatic skin and normal control and to correlate its expression with disease severity. Patients and methods This study was conducted on 30 patients with plaque psoriasis and 20 age-matched and sex-matched controls. Biopsies were obtained from the active plaque (lesional) and nonlesional skin of the patients and normal controls. CDK2 density was assessed by counting immunohistochemically positive nuclei in 1000 suprabasal keratinocytes at ×400 power fields. Results CDK2 was negative in normal control skin (no positive nuclear staining was seen in suprabasal keratinocytes). Meanwhile, the psoriatic group showed diffuse nuclear positivity in suprabasal cells. The density was significantly higher in lesional versus nonlesional skin. CDK2 density in lesional and nonlesional skin showed a statistically significant correlation with Psoriasis Area and Severity Index score (r=0.820 and 0.683, P<0.001 and <0.001, respectively). Conclusion CDK2 density is high in plaque psoriatic epidermis more than in nonlesional and control skin, and this was positively correlated with disease severity. It indicates that it may play a role in the development of psoriasis and may be a potential therapeutic target.
{"title":"Comparative analysis of cyclin-dependent kinase 2 density by immunohistochemistry in lesional versus nonlesional psoriatic skin","authors":"Eman H Elmorsy, Eman Alsawy, Basma Elsronbawy, Alsayeda A A Taha","doi":"10.4103/jewd.jewd_2_23","DOIUrl":"https://doi.org/10.4103/jewd.jewd_2_23","url":null,"abstract":"Background Psoriasis is a noninfectious, inflammatory, and hyperproliferative skin disorder. Cyclin-dependent kinase 2 (CDK2) is a serine-threonine protein kinase that plays a role in the transition of G1/S, the initiation of DNA synthesis, and the regulation of the S phase exit in the cell cycle. CDK2 is uniformly expressed in healthy human epidermis being located mainly in the cytoplasm and nuclei of basal keratinocytes. Objective To compare the CDK2 density by immunohistochemistry in lesional versus nonlesional psoriatic skin and normal control and to correlate its expression with disease severity. Patients and methods This study was conducted on 30 patients with plaque psoriasis and 20 age-matched and sex-matched controls. Biopsies were obtained from the active plaque (lesional) and nonlesional skin of the patients and normal controls. CDK2 density was assessed by counting immunohistochemically positive nuclei in 1000 suprabasal keratinocytes at ×400 power fields. Results CDK2 was negative in normal control skin (no positive nuclear staining was seen in suprabasal keratinocytes). Meanwhile, the psoriatic group showed diffuse nuclear positivity in suprabasal cells. The density was significantly higher in lesional versus nonlesional skin. CDK2 density in lesional and nonlesional skin showed a statistically significant correlation with Psoriasis Area and Severity Index score (r=0.820 and 0.683, P<0.001 and <0.001, respectively). Conclusion CDK2 density is high in plaque psoriatic epidermis more than in nonlesional and control skin, and this was positively correlated with disease severity. It indicates that it may play a role in the development of psoriasis and may be a potential therapeutic target.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"90 - 97"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47443400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omar El Ghanam, G. Enany, N. Nagui, H. Nada, E. El-Nabarawy, Iman Sany, A. Nada, A. Elbendary, Rana Mosaad
Pemphigus vulgaris is a chronic autoimmune bullous disease, which requires long-term treatment with immunosuppressive drugs that are associated with many complications. Iatrogenic Kaposi’s sarcoma (KS) is a variant of Kaposi sarcoma that might complicate long-term immunosuppressive therapy. Here, we report a pemphigus vulgaris patient who developed Kaposi’s sarcoma after a long-term treatment with corticosteroid and azathioprine.
{"title":"Iatrogenic Kaposi’s sarcoma: a report of rare association in a case of pemphigus vulgaris","authors":"Omar El Ghanam, G. Enany, N. Nagui, H. Nada, E. El-Nabarawy, Iman Sany, A. Nada, A. Elbendary, Rana Mosaad","doi":"10.4103/jewd.jewd_8_23","DOIUrl":"https://doi.org/10.4103/jewd.jewd_8_23","url":null,"abstract":"Pemphigus vulgaris is a chronic autoimmune bullous disease, which requires long-term treatment with immunosuppressive drugs that are associated with many complications. Iatrogenic Kaposi’s sarcoma (KS) is a variant of Kaposi sarcoma that might complicate long-term immunosuppressive therapy. Here, we report a pemphigus vulgaris patient who developed Kaposi’s sarcoma after a long-term treatment with corticosteroid and azathioprine.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"131 - 134"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48278875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vitamin D plays a vital role in skin diseases, and vitamin D supplementation seems to warrant protection against occurrence and exacerbation of several dermatological conditions. This review covers the immunopathological and therapeutic role of vitamin D, with a comprehensive illustration in some diseases.
{"title":"Vitamin D and the skin: an immunologic and therapeutic update","authors":"Naglaa N. El Mongy, R. Hilal","doi":"10.4103/jewd.jewd_55_22","DOIUrl":"https://doi.org/10.4103/jewd.jewd_55_22","url":null,"abstract":"Vitamin D plays a vital role in skin diseases, and vitamin D supplementation seems to warrant protection against occurrence and exacerbation of several dermatological conditions. This review covers the immunopathological and therapeutic role of vitamin D, with a comprehensive illustration in some diseases.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"69 - 80"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46929546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. E. El Mulla, Doaa Khalifa, Rasha Gawish, M. Eldeeb
Background Chronic kidney disease-associated pruritus (CKD-AP) is a challenging disorder with unsatisfactory treatment response. The exact pathophysiology is unknown. Phototherapy and pregabalin are commonly used treatment options. Narrow band-ultraviolet B (NB-UVB) acts by inhibition of Langerhans cells, modulation of interleukin production, and induction of apoptosis of mast cells. Pregabalin acts by suppressing presynaptic glutamate release through inhibition of calcium currents via high-voltage active channels, leading to reduced neurotransmitter release and attenuation of postsynaptic excitability. Objective To compare the safety and efficacy of NB-UVB versus pregabalin in the treatment of refractory CKD-AP. Patients and methods A prospective randomized controlled study included 40 patients on maintenance hemodialysis with refractory pruritus. Patients were randomized into two groups: group A (20 patients) received two sessions of NB-UVB per week for a period of 2 months, and group B (20 patients) received pregabalin (50 mg after each dialysis session) for 2 months. The results of the present study were assessed by total 5-D itch score (after 4, 8, and 12 weeks). Results Both groups showed significant reduction in itching severity by the end of treatment (week 8) but recurrence of symptoms during follow-up (week 12) was observed, with no significant difference between both groups. However, fewer adverse effects, earlier onset of response, and less tendency of recurrence were observed in the NB-UVB group. Conclusion NB-UVB and pregabalin are both effective options in controlling refractory CKD-AP. Rapid control and delayed recurrence of symptoms favor NB-UVB.
{"title":"Phototherapy versus pregabalin in treatment of chronic kidney disease associated pruritus: randomized controlled study","authors":"K. E. El Mulla, Doaa Khalifa, Rasha Gawish, M. Eldeeb","doi":"10.4103/jewd.jewd_50_22","DOIUrl":"https://doi.org/10.4103/jewd.jewd_50_22","url":null,"abstract":"Background Chronic kidney disease-associated pruritus (CKD-AP) is a challenging disorder with unsatisfactory treatment response. The exact pathophysiology is unknown. Phototherapy and pregabalin are commonly used treatment options. Narrow band-ultraviolet B (NB-UVB) acts by inhibition of Langerhans cells, modulation of interleukin production, and induction of apoptosis of mast cells. Pregabalin acts by suppressing presynaptic glutamate release through inhibition of calcium currents via high-voltage active channels, leading to reduced neurotransmitter release and attenuation of postsynaptic excitability. Objective To compare the safety and efficacy of NB-UVB versus pregabalin in the treatment of refractory CKD-AP. Patients and methods A prospective randomized controlled study included 40 patients on maintenance hemodialysis with refractory pruritus. Patients were randomized into two groups: group A (20 patients) received two sessions of NB-UVB per week for a period of 2 months, and group B (20 patients) received pregabalin (50 mg after each dialysis session) for 2 months. The results of the present study were assessed by total 5-D itch score (after 4, 8, and 12 weeks). Results Both groups showed significant reduction in itching severity by the end of treatment (week 8) but recurrence of symptoms during follow-up (week 12) was observed, with no significant difference between both groups. However, fewer adverse effects, earlier onset of response, and less tendency of recurrence were observed in the NB-UVB group. Conclusion NB-UVB and pregabalin are both effective options in controlling refractory CKD-AP. Rapid control and delayed recurrence of symptoms favor NB-UVB.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"81 - 89"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43778145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alsayeda A A Taha, N. Khadr, D. Elneily, M. Elkhalifa, Sara Mohamad
Background Psoriasis is a common, multifactorial, chronic inflammatory disorder that affects the skin and is increasingly recognized to be a systemic inflammatory disease. The quality of life is significantly affected by the highly heritable polygenic condition known as psoriatic arthritis (PsA). The care of PsA and early identification and detection of the condition will enhance quality of life and reduce complications. Detection of serum biomarker for PsA may help in early diagnosis. Objective To compare the serum levels of matrix metalloproteinase-3 (MMP-3) in patients with psoriasis with and without PsA and its correlation with disease severity. Patients and methods This case–control study was conducted on 40 patients with psoriasis and 20 age-matched and sex-matched controls. Patients were divided according to CASPAR criteria into two groups: psoriasis group (A) and PsA group (B). Enzyme-linked immunosorbent assay was used to determine the serum level of MMP-3. Results There was no statistically significant difference of MMP-3 level between psoriatic without PsA and control groups. There was a statistically significant higher level of MMP-3 in the PsA group compared with both psoriatic and control groups (mean=33.20±26.86, 16.24±14.80, and 16.47±8.43 pg/ml, respectively), and it was not correlated with disease severity in patients with psoriasis. Conclusion Serum levels of MMP-3 were significantly higher in psoriatic patients with arthritis compared with both psoriatic and control groups. Therefore, it may have a role in the development of PsA and may be used as a marker for diagnosis; however, it is not correlated with disease severity.
{"title":"Serum matrix metalloproteinase-3 in patients with psoriasis with and without arthritis","authors":"Alsayeda A A Taha, N. Khadr, D. Elneily, M. Elkhalifa, Sara Mohamad","doi":"10.4103/jewd.jewd_5_23","DOIUrl":"https://doi.org/10.4103/jewd.jewd_5_23","url":null,"abstract":"Background Psoriasis is a common, multifactorial, chronic inflammatory disorder that affects the skin and is increasingly recognized to be a systemic inflammatory disease. The quality of life is significantly affected by the highly heritable polygenic condition known as psoriatic arthritis (PsA). The care of PsA and early identification and detection of the condition will enhance quality of life and reduce complications. Detection of serum biomarker for PsA may help in early diagnosis. Objective To compare the serum levels of matrix metalloproteinase-3 (MMP-3) in patients with psoriasis with and without PsA and its correlation with disease severity. Patients and methods This case–control study was conducted on 40 patients with psoriasis and 20 age-matched and sex-matched controls. Patients were divided according to CASPAR criteria into two groups: psoriasis group (A) and PsA group (B). Enzyme-linked immunosorbent assay was used to determine the serum level of MMP-3. Results There was no statistically significant difference of MMP-3 level between psoriatic without PsA and control groups. There was a statistically significant higher level of MMP-3 in the PsA group compared with both psoriatic and control groups (mean=33.20±26.86, 16.24±14.80, and 16.47±8.43 pg/ml, respectively), and it was not correlated with disease severity in patients with psoriasis. Conclusion Serum levels of MMP-3 were significantly higher in psoriatic patients with arthritis compared with both psoriatic and control groups. Therefore, it may have a role in the development of PsA and may be used as a marker for diagnosis; however, it is not correlated with disease severity.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"125 - 130"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44202339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ghazal Ahmed, Anju George C, Jemshi Raim, Satyaki Ganguly
{"title":"The ‘rat-bitten ear’: a rare case of multifocal ulcerated lupus panniculitis","authors":"Ghazal Ahmed, Anju George C, Jemshi Raim, Satyaki Ganguly","doi":"10.4103/jewd.jewd_43_22","DOIUrl":"https://doi.org/10.4103/jewd.jewd_43_22","url":null,"abstract":"","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"143 - 145"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47548856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Vitiligo is a chronic acquired disorder resulting from the destruction of epidermal melanocytes owing to multifactorial causes. Various cytokines play a central role in its pathogenesis. Interleukin (IL)-33 has an essential role in different autoimmune diseases; however, scarce data are available about its role in vitiligo as an activity marker. Objective To evaluate serum IL-33 levels in patients with active and stable vitiligo. Patients and methods A case–control study was conducted on 75 participants: 25 patients with active nonsegmental vitiligo (NSV), 25 with stable NSV, and 25 age-matched and sex-matched controls. The disease characteristics of vitiligo were reported regarding activity, duration, type, and extent. The vitiligo disease activity (VIDA) score was used to evaluate the disease activity. The serum level of IL-33 was measured by enzyme-linked immunosorbent assay in all groups. Results The serum IL-33 levels showed no significant difference (P=0.996) between active cases (mean=1378±1102.66 ng/l) and stable NSV cases (mean=1397±948.97 ng/l); however, a highly significant difference (P<0.001) was found between active/stable cases and controls (mean=230.00±55.90 ng/l). No relation was found between IL-33 levels and the patient’s age (P=0.288), duration of vitiligo (P=0.67), duration of last activity (P=0.149), VIDA score (P=0.377), vitiligo extent (P=0.377), sex (P=0.217), or vitiligo types (P=0.383). Conclusion IL-33 may have a pivotal role in the immune dysregulation of NSV vitiligo. However, it cannot be used as a discriminating serum marker between active and stable cases.
{"title":"Evaluation of serum interleukin-33 as an activity serum marker for nonsegmental vitiligo","authors":"N. Khafagy, A. Magdeldin, M. Ibrahim","doi":"10.4103/jewd.jewd_58_22","DOIUrl":"https://doi.org/10.4103/jewd.jewd_58_22","url":null,"abstract":"Background Vitiligo is a chronic acquired disorder resulting from the destruction of epidermal melanocytes owing to multifactorial causes. Various cytokines play a central role in its pathogenesis. Interleukin (IL)-33 has an essential role in different autoimmune diseases; however, scarce data are available about its role in vitiligo as an activity marker. Objective To evaluate serum IL-33 levels in patients with active and stable vitiligo. Patients and methods A case–control study was conducted on 75 participants: 25 patients with active nonsegmental vitiligo (NSV), 25 with stable NSV, and 25 age-matched and sex-matched controls. The disease characteristics of vitiligo were reported regarding activity, duration, type, and extent. The vitiligo disease activity (VIDA) score was used to evaluate the disease activity. The serum level of IL-33 was measured by enzyme-linked immunosorbent assay in all groups. Results The serum IL-33 levels showed no significant difference (P=0.996) between active cases (mean=1378±1102.66 ng/l) and stable NSV cases (mean=1397±948.97 ng/l); however, a highly significant difference (P<0.001) was found between active/stable cases and controls (mean=230.00±55.90 ng/l). No relation was found between IL-33 levels and the patient’s age (P=0.288), duration of vitiligo (P=0.67), duration of last activity (P=0.149), VIDA score (P=0.377), vitiligo extent (P=0.377), sex (P=0.217), or vitiligo types (P=0.383). Conclusion IL-33 may have a pivotal role in the immune dysregulation of NSV vitiligo. However, it cannot be used as a discriminating serum marker between active and stable cases.","PeriodicalId":17298,"journal":{"name":"Journal of the Egyptian Women's Dermatologic Society","volume":"20 1","pages":"120 - 124"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48478572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：